No abstract available.
Female ; Metrorrhagia*

No abstract available.
Female ; Metrorrhagia*

No abstract available.
Female ; Metrorrhagia*

OBJECTIVE: to test the safety of ultrasound imaging guided high intensity focused ultrasound (HIFU) to ablate uterine myoma. METHODS: From September 2008 to February 2009, patients with dysmenorrhea and/or menorrhagia for uterine myomas had been enrolled. HIFU ablation was performed at 1 MHz. 400 W/cm2 of pulses were delivered for 150 m second with 150 m second interval at the target point for 70 cycles. This process was repeated on a point by point basis. After one slice was treated, the target was shifted 4 mm laterally. If patient were complaining of pain, the procedures were stopped for a while. RESULTS: The distribution of age was 29~48 years old, and of longest diameter was 36.0~115.0 mm, and of target distance from skin was 55~100 mm, and of number of treatment was 2~6. Nobody gave up the procedure for pain or any other reason. The procedures took 40 to 60 minutes for a slice. One or three slices were treated in a day. All patients went home after HIFU without medication. Nobody reported any clinically severe complications. Everybody returned to normal activities 1 day after the procedure. Nobody complained of vaginal spotting after one cycle of menstruation. CONCLUSION: Ultrasound imaging-guided HIFU treatment appears to be safe to ablate the uterine myomas.
Dysmenorrhea ; Female ; Humans ; Menorrhagia ; Menstruation ; Metrorrhagia ; Myoma ; Skin

OBJECTIVE: To analyze the clinical experiences of patients who treated with levonorgestrel-releasing intrauterine system (LNG-IUS) for adenomyosis associated with dysmenorrhea and/or menorrhagia. METHODS: The LNG-IUS was inserted into 103 patients who were diagnosed with adenomyosis on ultrasound examination and suffered from dysmenorrhea or menorrhagia at CHA Gangnam Medical Center between January 2009 and December 2009. Symptomatic changes of dysmenorrhea and menorrhagia, side effects, and failure rates were evaluated, retrospectively. RESULTS: During the follow-up periods, dysmenorrhea was improved in 91.4% and menorrhagia was improved in 90.4% of patients. Most common side effects were prolonged vaginal spotting in 41 (39.8%), and expulsion of LNG-IUS in 32 (31.1%) patients. Six (5.7%) patients were premature removal of LNG-IUS and 9 (8.5%) patients were underwent hysterectomy. Overall 77 (74.8%) patients continued to use of LNG-IUS. CONCLUSION: The LNG-IUS is effective treatment option for management of dysmenorrhea and menorrhagia for patients with clinical diagnosis of adenomyosis. It seemed to be an alternative treatment method before hysterectomy.
Adenomyosis ; Dysmenorrhea ; Female ; Follow-Up Studies ; Humans ; Hysterectomy ; Menorrhagia ; Metrorrhagia

Leiomyosarcomas comprise fewer than 2% of all malignant vaginal neoplasms. Due to their rarity, treatment for vaginal leiomyosarcomas have not been determined. We describe a 66 year old woman with vaginal leiomyosarcoma, which presented as a large palpable mass with vaginal spotting. Complete surgical excision was accomplished and after surgery, she underwent radiation therapy. Tumor recurrence was not detected for the last 5 years and now her general condition is very good. This is a rare case of leiomyosarcoma arising in vagina and we report the results of successful treatment.
Female ; Humans ; Leiomyosarcoma ; Metrorrhagia ; Recurrence ; Vagina ; Vaginal Neoplasms

Leiomyosarcomas comprise fewer than 2% of all malignant vaginal neoplasms. Due to their rarity, treatment for vaginal leiomyosarcomas have not been determined. We describe a 66 year old woman with vaginal leiomyosarcoma, which presented as a large palpable mass with vaginal spotting. Complete surgical excision was accomplished and after surgery, she underwent radiation therapy. Tumor recurrence was not detected for the last 5 years and now her general condition is very good. This is a rare case of leiomyosarcoma arising in vagina and we report the results of successful treatment.
Female ; Humans ; Leiomyosarcoma ; Metrorrhagia ; Recurrence ; Vagina ; Vaginal Neoplasms

Hormone therapy for peri- and postmenopausal women is widely used for relieving vasomotor symptoms or preventing osteoporosis. Even though exogenous hormone is the most common cause of vaginal bleeding in postmenopausal women under hormone therapy, in clinical practice, physicians must never exclude the possibility of endometrial disorders, such as endometrial hyperplasia or cancer. Taking thorough medical history and performing physical and pelvic examinations are essential for the evaluation of abnormal uterine bleeding in menopausal hormone therapy. Transvaginal ultrasonography, endometrial aspiration biopsy, dilatation and curettage, and hysteroscopy are the options which physicians may use. This case is about a woman with continuous combined hormone therapy for 5 years who had experienced rather sudden onset of vaginal spotting lasting for several months and was finally diagnosed as having malignant mixed Mullerian tumor. Our purpose is to inquire into the proper approaching steps for vaginal bleeding in menopausal hormone therapy.
Biopsy, Needle ; Dilatation and Curettage ; Endometrial Hyperplasia ; Female ; Gynecological Examination ; Humans ; Hysteroscopy ; Metrorrhagia ; Osteoporosis ; Uterine Hemorrhage

The concept of mosaicism has been used to explain different cutaneous patterns, such as the lines of Blaschko, the checkerboard pattern, the phylloid pattern, and a patchy pattern. Many mosaic patterns are caused by loss of heterozygosity, the genetic mechanism by which a heterozygous somatic cell becomes either homozygous or hemizygous. A particular form of loss of heterozygosity is twin spotting, which give rise to two contrary homozygous daughter cells. The concept of twin spotting has been used for some of these human phenotypes, which are characterized by the co-occurrence of two different nevi, including nevus vascularis mixtus. Nevus vascularis mixtus is a rare vascular malformation characterized by the coexistence of a nevus anemicus and a nevus telangiectaticus, and can be associated with extra-cutaneous anomalies, such as cerebral malformations. Herein, we report a 6-year-old girl with paired cutaneous vascular nevi telangiectaticus, anemicus, and nevus vascularis mixtus, that were distributed on the left side of her chest and left arm, without other systemic and neurologic anomalies.
Arm ; Child ; Female ; Humans ; Loss of Heterozygosity ; Metrorrhagia ; Mosaicism ; Nevus* ; Nuclear Family ; Phenotype ; Thorax ; Twins ; Vascular Malformations

Oral contraceptive user had less menstrual blood loss, which reduced the risk of iron deificiency anemia by 50%. The incidence of menorrhagia, irregular menses and intermenstrual bleeding is also singificantly reduced in the user of oral contraceptives. In most women with leiomyomas, low-dose oral contraceptive use provide the noncontraceptive benefit of a reduction of menstrual flow, with resultant improvement in hematocrit. So, we confirmed that anemic leiomyoma patients with oral contraceptive use showed autotransfusion effects given by preoperative administration orally during some period.
Anemia ; Blood Transfusion, Autologous* ; Contraceptives, Oral ; Female ; Hematocrit ; Humans ; Incidence ; Iron ; Leiomyoma ; Menorrhagia ; Metrorrhagia ; Myoma